Sensitive: D – Preclinical
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
...Sacituzumab govitecan (SG)...Trop-2 expression by IHC was detected in 95.1% of USC samples (99/104). Primary tumor cell-lines overexpressing Trop-2 were significantly more sensitive to SG when compared to control ADC ( p < 0.05). SG is remarkably active against...Uterine serous carcinoma (USC)...overexpressing Trop-2 in vitro and in vivo.